Anales Oftalmológicos

17 / 52

17
Glaucoma Neovascular
BIBLIOGRAFÍA
1. Albert DM, Jakobiec FA. Neovascular
Glaucoma. In: Albert DM, Jakobiec FA, editors.
Principles and practice of ophthalmology.
1999, Philadel‑ phia: WB Saunders Publishers.
2. Coats G: Further cases of thrombosis of the
central vein. Roy Lond Ophthal Hosp Rep 1906;
16: 516.
3. Mocanu C, Barascu D, Marinescu F,
Lacrateanu M, Iliusi F, Simionescu C:
Neovascular glaucoma – retrospective study
(in Romanian). Oftalmologia 2005; 49: 58–65.
4. The Central Vein Occlusion Study Group
Natural history and clinical management
of central retinal vein occlusion, Arch
Ophthalmol, 115 (1997), pp. 486-491
5. Klein et al, The Beaver Dam Eye Study, ARCH
OPHTHALMOL/VOL 126 (NO. 4), APR 2008
6. Encuesta Nacional de Salud 2009-2010 (ENS):
.
7. International Diabetes Federation 2015. www.
8. Rodrigues et al, Neovascular glaucoma: a
review, International Journal of Retina and
Vitreus, 2:26 2016
9. Aiello LP, et al. Vascular endothelial growth
factor in ocular fluid of patients with diabetic
retinopathy and other retinal disorders. N Engl
J Med. 1994;331(22):1480–7.
10. Sall JW, et al. Somatostatin inhibits IGF‑1
mediated induction of VEGF in human
retinal pigment epithelial cells. Exp Eye Res.
2004;79(4):465–76
11. Ruberte J, et al. Increased ocular levels of
IGF‑1 in transgenic mice lead to diabetes‑like
eye disease. J Clin Invest. 2004;113(8):1149–57
12. Fernandez‑Vigo J, Castro J, Macarro A.
Diabetic iris neovascu‑ larization. Natural
history and treatment. Acta Ophthalmol Scand.
1997;75(1):89–9
13. Chen HF, Chen MC, Chuang LH, Chen HF,
Chen MC, Lai CC, Yeung L, Wang NK, Chen
HS, Ku WC, Wu SC, Chang SH, Chuang LH.
Neovascular glaucoma after central retinal
vein occlusion in pre‑existing glaucoma. BMC
Opthalmol. 2014;5(14):119
14. Baseline and early natural history report. The
Central Vein Occlusion Study. Arch Ophthalmol
1993; 111: 1087–1095. 23
15. Lang GE. Laser treatment of diabetic
retinopathy. Dev Ophthalmol. 2007;39:48–68
16. Wang JW, et al. Short‑term effect of
intravitreal ranibizumab on intraocular
concentrations of vascular endothelial growth
factor‑A and pigment epithelium‑derived
factor in neovascular glaucoma. Clin Exp
Ophthalmol. 201
17. Zhou et al, Clinical Outcomes of Ahmed
Glaucoma Valve Implantation With or Without
Intravitreal Bevacizumab Pretreatment for
Neovascular Glaucoma: A Systematic Review
and Meta-Analysis, Journal Glaucoma January
2015
18. Kobayashi et al, Long-term Outcomes
After Preoperative Intravitreal Injection of
Bevacizumab Before Trabeculectomy for
Neovascular Glaucoma, Journal Glaucoma
Volume 25, Number 3, March 2016
CONCLUSIÓN
El Glaucoma Neovascular continua siendo un desafío
y causa importante de ceguera evitable, por lo que
se debe sospechar, tratar y seguir en el tiempo
en aquellos pacientes que presenten factores de
riesgo asociados. Es fundamental establecer un plan
terapéutico en estos pacientes de acuerdo a la etapa
en la que se encuentran considerando siempre un
adecuado control metabólico de sus patologías de
base, con el objetivo de detener su progresión (PFC-
Anti-VEGF), reducir la PIO mejorando el pronóstico
visual y el control de los síntomas deletéreos en la
calidad de vida de estos pacientes.